Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC

Resistance to EGFR inhibitors in EGFR mutant NSCLC is a major challenge,with resistance often through re-activation of MEK/ERK and PI3K pathways or through loss of cell death responses. This book is a valuable resource for cancer researchers, clinicians, graduate students, and other members of the biomedical field interested in promising treatments for lung cancer.

Format: Hardback
Length: 150 pages
Publication date: 01 February 2023
Publisher: Elsevier Science Publishing Co Inc

EGFR Mutant NSCLC: Overcoming Resistance to EGFR Inhibitors

EGFR mutant lung cancers have evolved sophisticated mechanisms to evade EGFR inhibitors, presenting a significant challenge in the treatment of this disease. In this comprehensive book, experts in the field provide updated information on the mechanisms of resistance, clinical strategies for identifying these mechanisms, and innovative therapeutic approaches to combat resistance and improve patient survival.

Resistance to EGFR inhibitors in EGFR mutant NSCLC often arises through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses. This overlap with resistance to targeted therapies in other cancer paradigms, such as BRAF inhibitors in BRAF mutant melanoma and HER2 inhibitors in HER2 amplified breast cancer, highlights the complexity of treating lung cancer.

Understanding these resistance mechanisms is crucial for developing effective treatment strategies. The book explores various clinical approaches, including molecular profiling, imaging techniques, and targeted therapies, that can help identify and target resistant pathways. It also discusses the use of combination therapies, immunotherapy, and precision medicine approaches to enhance the efficacy of EGFR inhibitor treatments.

Furthermore, the book emphasizes the importance of patient selection and personalized medicine in lung cancer treatment. It discusses the use of biomarkers and genetic testing to identify patients who are most likely to benefit from EGFR inhibitor treatments and to tailor treatment plans accordingly. This approach aims to maximize the benefits of therapy while minimizing the risk of side effects and improving patient outcomes.

Cancer researchers, clinicians, graduate students, and other members of the biomedical field interested in promising treatments for lung cancer will find this book a valuable resource. It provides a comprehensive overview of the current state of knowledge in EGFR mutant NSCLC resistance and offers insights into emerging therapeutic strategies. By leveraging the latest research and clinical expertise, this book aims to empower healthcare professionals to provide optimal care for patients with EGFR mutant lung cancer.

In conclusion, EGFR Mutant NSCLC: Overcoming Resistance to EGFR Inhibitors is a timely and essential resource for anyone seeking to advance their understanding of resistance mechanisms and develop effective treatment strategies for this challenging disease. By leveraging the latest research and clinical expertise, this book aims to improve patient outcomes and ultimately lead to a better understanding and treatment of lung cancer.

Dimension: 235 x 191 (mm)
ISBN-13: 9780128228333